

# Borislava Mihaylova

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2850379/publications.pdf>

Version: 2024-02-01

77  
papers

24,998  
citations

201674

27  
h-index

102487

66  
g-index

77  
all docs

77  
docs citations

77  
times ranked

21228  
citing authors

#	ARTICLE	IF	CITATIONS
1	Performance of the UK Prospective Diabetes Study Outcomes Model 2 in a Contemporary UK Type 2 Diabetes Trial Cohort. <i>Value in Health</i> , 2022, 25, 435-442.	0.3	4
2	Daily Life and Challenges Faced By Households With Permanent Childhood Developmental Disability in Rural Tanzania – A Qualitative Study. <i>Journal of Developmental and Physical Disabilities</i> , 2022, 34, 471-490.	1.6	3
3	P55 Excess Annual Hospital Costs Due to Cardiovascular Events in a Contemporary UK Population to Inform Health Technology Assessments. <i>Value in Health</i> , 2022, 25, S12.	0.3	0
4	P70 Calibrating Cardiovascular Disease Policy Model Using Large Cohort Data. <i>Value in Health</i> , 2022, 25, S16.	0.3	0
5	Decrements in health-related quality of life associated with adverse events in people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 530-538.	4.4	9
6	Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. <i>European Heart Journal</i> , 2022, 43, 1416-1424.	2.2	27
7	Hospital costs associated with adverse events in people with diabetes in the <scp>UK</scp>. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2108-2117.	4.4	5
8	The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2021, 99, 34-47.	5.2	195
9	Impact of the 2003 to 2018 Population Salt Intake Reduction Program in England. <i>Hypertension</i> , 2021, 77, 1086-1094.	2.7	21
10	Content of Health Economics Analysis Plans (HEAPs) for Trial-Based Economic Evaluations: Expert Delphi Consensus Survey. <i>Value in Health</i> , 2021, 24, 539-547.	0.3	28
11	Gender differences in use of invasive diagnostic and therapeutic procedures for acute ischaemic heart disease in Chinese adults. <i>Heart</i> , 2021, , heartjnl-2021-318988.	2.9	3
12	Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90). <i>Diabetic Medicine</i> , 2021, 38, e14656.	2.3	10
13	Supported online self-management versus care as usual for symptoms of fatigue, pain and urgency/incontinence in adults with inflammatory bowel disease (IBD-BOOST): study protocol for a randomised controlled trial. <i>Trials</i> , 2021, 22, 516.	1.6	11
14	Long-term monitoring in primary care for chronic kidney disease and chronic heart failure: a multi-method research programme. <i>Programme Grants for Applied Research</i> , 2021, 9, 1-218.	1.0	1
15	Benefits from optimised antihypertensive and statin treatment in high risk people. <i>European Heart Journal</i> , 2021, 42, .	2.2	1
16	A model of lifetime health outcomes in cardiovascular disease based on clinical trials and large cohorts. <i>European Heart Journal</i> , 2021, 42, .	2.2	0
17	Gaps in antihypertensive and statin treatments and benefits of optimisation: a modelling study in a 1 million ethnically diverse urban population in UK. <i>BMJ Open</i> , 2021, 11, e052884.	1.9	2
18	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 111-188.	2.2	4,871

#	ARTICLE	IF	CITATIONS
19	Socioeconomic differences in health-care use and outcomes for stroke and ischaemic heart disease in China during 2009â€“16: a prospective cohort study of 0.5 million adults. <i>The Lancet Global Health</i> , 2020, 8, e591-e602.	6.3	19
20	BMI and Cause-Specific Hospital Admissions and Costs: The UK Biobank Cohort Study. <i>Obesity</i> , 2020, 28, 1332-1341.	3.0	9
21	Long-term health outcomes of people with reduced kidney function in the UK: A modelling study using population health data. <i>PLoS Medicine</i> , 2020, 17, e1003478.	8.4	7
22	Title is missing!. , 2020, 17, e1003478.		0
23	Title is missing!. , 2020, 17, e1003478.		0
24	Title is missing!. , 2020, 17, e1003478.		0
25	Title is missing!. , 2020, 17, e1003478.		0
26	Title is missing!. , 2020, 17, e1003478.		0
27	Impact of <i>ADCY9</i> Genotype on Response to Anacetrapib. <i>Circulation</i> , 2019, 140, 891-898.	1.6	34
28	Impact of achieving primary care targets in type 2 diabetes on health outcomes and healthcare costs. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2405-2412.	4.4	10
29	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. <i>Atherosclerosis</i> , 2019, 290, 140-205.	0.8	1,753
30	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. <i>Lancet, The</i> , 2019, 393, 407-415.	13.7	512
31	Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. <i>Kidney International</i> , 2019, 96, 170-179.	5.2	13
32	Is Doctor Referral to a Low-Energy Total Diet Replacement Program Cost-Effective for the Routine Treatment of Obesity?. <i>Obesity</i> , 2019, 27, 391-398.	3.0	20
33	Declining socioeconomic inequalities in hospital care use and case fatality rates for stroke and ischaemic heart disease in China during 2009â€“16: a prospective study of 0.5 million adults. <i>Lancet, The</i> , 2019, 394, S9.	13.7	0
34	Optimisation of Perioperative Cardiovascular Management to Improve Surgical Outcome II (OPTIMISE II) trial: study protocol for a multicentre international trial of cardiac output-guided fluid therapy with low-dose inotrope infusion compared with usual care in patients undergoing major elective gastrointestinal surgery. <i>BMJ Open</i> , 2019, 9, e023455.	1.9	35
35	Body mass index and use and costs of primary care services among women aged 55â€“79 years in England: a cohort and linked data study. <i>International Journal of Obesity</i> , 2019, 43, 1839-1848.	3.4	11
36	An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment. <i>Journal of Clinical Epidemiology</i> , 2018, 99, 75-83.	5.0	25

#	ARTICLE	IF	CITATIONS
37	Impact of CKD on Household Income. <i>Kidney International Reports</i> , 2018, 3, 610-618.	0.8	25
38	Household costs and time to treatment for children with severe febrile illness in rural Burkina Faso: the role of rectal artesunate. <i>Malaria Journal</i> , 2018, 17, 380.	2.3	2
39	Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2015-2027.	6.1	140
40	Authors'™ Reply. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2602.2-2603.	6.1	0
41	Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)â€”A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics. <i>American Heart Journal</i> , 2017, 187, 182-190.	2.7	66
42	Hospital costs in relation to body-mass index in 1Â·1 million women in England: a prospective cohort study. <i>Lancet Public Health</i> , The, 2017, 2, e214-e222.	10.0	30
43	Body mass index and healthcare costs: a systematic literature review of individual participant data studies. <i>Obesity Reviews</i> , 2017, 18, 869-879.	6.5	91
44	Choices of Stent and Cerebral Protection in the Ongoing ACST-2 Trial: A Descriptive Study. <i>European Journal of Vascular and Endovascular Surgery</i> , 2017, 53, 617-625.	1.5	12
45	The INVEST project: investigating the use of evidence synthesis in the design and analysis of clinical trials. <i>Trials</i> , 2017, 18, 219.	1.6	14
46	Cholesterol- and blood-pressure-lowering drug use for secondary cardiovascular prevention in 2004â€”2013 Europe. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 426-436.	1.8	10
47	A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease. <i>Heart</i> , 2017, 103, 1880-1890.	2.9	21
48	Meta-analysis of the procedural risks of carotid endarterectomy and carotid artery stenting over time. <i>British Journal of Surgery</i> , 2017, 105, 26-36.	0.3	57
49	Impact of Improving Community-Based Access to Malaria Diagnosis and Treatment on Household Costs. <i>Clinical Infectious Diseases</i> , 2016, 63, S256-S263.	5.8	6
50	Are statins useful in patients with advanced chronic kidney disease? â€” Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , the, 2016, 4, 971-972.	11.4	7
51	Quantifying and Valuing Community Health Worker Time in Improving Access to Malaria Diagnosis and Treatment. <i>Clinical Infectious Diseases</i> , 2016, 63, S298-S305.	5.8	8
52	Health Economics Analysis Plans: Where Are We Now ?. <i>Value in Health</i> , 2016, 19, A397.	0.3	24
53	Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. <i>Lancet Diabetes and Endocrinology</i> , the, 2016, 4, 829-839.	11.4	234
54	Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 348-354.	2.2	8

#	ARTICLE	IF	CITATIONS
55	Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD. American Journal of Kidney Diseases, 2016, 67, 31-39.	1.9	42
56	Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases, 2016, 67, 576-584.	1.9	19
57	Protocol for analyses of adverse event data from randomized controlled trials of statin therapy. American Heart Journal, 2016, 176, 63-69.	2.7	22
58	The impact of social disadvantage in moderate-to-severe chronic kidney disease: an equity-focused systematic review*. Nephrology Dialysis Transplantation, 2016, 31, 46-56.	0.7	76
59	FP329IMPACT OF EDUCATIONAL ATTAINMENT ON HEALTH OUTCOMES IN MODERATE-TO-SEVERE CHRONIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2015, 30, iii178-iii178.	0.7	1
60	What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?. BMC Nephrology, 2015, 16, 65.	1.8	82
61	The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS) Tj ETQq1, 1, 0.784314 rgBT 160	2.3	160
62	Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. Lancet, The, 2015, 385, 1397-1405.	13.7	1,112
63	Out-of-Pocket Costs and Other Determinants of Access to Healthcare for Children with Febrile Illnesses: A Case-Control Study in Rural Tanzania. PLoS ONE, 2015, 10, e0122386.	2.5	8
64	THE EFFECT OF DIABETES COMPLICATIONS ON HEALTH-RELATED QUALITY OF LIFE: THE IMPORTANCE OF LONGITUDINAL DATA TO ADDRESS PATIENT HETEROGENEITY. Health Economics (United Kingdom), 2014, 23, 487-500.	1.7	84
65	The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet, The, 2012, 380, 581-590.	13.7	2,250
66	Statins for people at low risk of cardiovascular disease – Authors' reply. Lancet, The, 2012, 380, 1817-1818.	13.7	127
67	Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial. Lancet, The, 2011, 378, 2013-2020.	13.7	244
68	Review of statistical methods for analysing healthcare resources and costs. Health Economics (United Kingdom), 2011, 20, 897-916.	1.7	574
69	Cost-Effectiveness of Duloxetine: The Stress Urinary Incontinence Treatment (SUIT) Study. Value in Health, 2010, 13, 565-572.	0.3	14
70	Cost-Effectiveness of Pre-Referral Antimalarial, Antibacterial, and Combined Rectal Formulations for Severe Febrile Illness. PLoS ONE, 2010, 5, e14446.	2.5	7
71	Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart, 2007, 93, 1081-1086.	2.9	53
72	Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20 536 people. BMJ: British Medical Journal, 2006, 333, 1145.	2.3	80

#	ARTICLE	IF	CITATIONS
73	Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20â€™536 individuals. <i>Lancet, The</i> , 2005, 365, 1779-1785.	13.7	106
74	MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. <i>Lancet, The</i> , 2003, 361, 2005-2016.	13.7	2,587
75	MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20â€™536 high-risk individuals: a randomised placebocontrolled trial. <i>Lancet, The</i> , 2002, 360, 7-22.	13.7	7,542
76	MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20â€™536 high-risk individuals: a randomised placebo-controlled trial. <i>Lancet, The</i> , 2002, 360, 23-33.	13.7	1,413
77	Statistical models for the deterioration of kidney function in a primary care population: A retrospective database analysis. <i>F1000Research</i> , 0, 8, 1618.	1.6	1